Summit Therapeutics plc
(“Summit” or “the Company”)

SUMMIT THERAPEUTICS TO PRESENT PHASE 1B CLINICAL AND PRECLINICAL DMD DATA AT THE 20TH INTERNATIONAL CONGRESS OF THE WORLD MUSCLE SOCIETY

Oxford, UK, 24 September 2015 – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, today announced that it will present additional clinical data from its Phase 1b modified diet trial of SMT C1100 for the treatment of DMD, as well as preclinical data supporting SMT C1100 and the broader utrophin modulation pipeline, at the 20th International Congress of the World Muscle Society, taking place 30 September-4 October 2015 in Brighton, UK.

The posters will be available in the Corn Exchange, Brighton from the beginning of the conference on 30 September 2015 and a press release containing key data from the presentations will be issued on that date. Details of the poster presentations are as follows:

Clinical:

Date & Time: Friday 2 October, 3:00-4:30pm BST
Session: Guided Poster Session 3
Abstract Number: G.P. 249
Title: Utrophin modulators to treat Duchenne muscular dystrophy (DMD): Results from a Phase 1b Clinical Trial of SMT C1100
Authors: F. Muntoni; S. Spinty; H. Roper; I. Hughes; V. Ricotti; B. Tejura; G. Layton; K. Davies and J. Tinsley

Preclinical:

Date & Time: Friday 2 October, 3:00-4:30pm BST
Session: Guided Poster Session 3
Abstract Number: G.P. 216
Title: Biomarker development to support the clinical development of utrophin modulators for Duchenne muscular dystrophy therapy
Authors: J. Tinsley; N. Janghra; J. Morgan; C. Sewry; F. Muntoni; D. Elsey; F. Wilson; K. Davies

Date & Time: Friday 2 October, 3:00-4:30pm BST
Session: Guided Poster Session 3
Abstract Number: G.P. 245
Title: Second generation utrophin modulator for the therapy of Duchenne muscular dystrophy
Authors: S. Guiraud; S. Squire; B. Edwards; H. Chen; D. Burns; N. Shah; A. Babbs; S. Davies; G. Wynne; A. Russell; D. Elsey; F. Wilson; J. Tinsley; K. Davies

Date & Time: Friday 2 October, 3:00-4:30pm BST
Session: Guided Poster Session 3
Abstract Number: G.P. 246
Title: Utrophin modulators significantly improve muscular dystrophy in the mdx diaphragm
Authors: S. Guiraud; H. Chen; S. Squire; B. Edwards; D. Burns; N. Shah; S. Davies; G. Wynne; A. Russell; D. Elsey; F. Wilson; J. Tinsley; K. Davies
About the Phase 1b Modified Diet Trial
The Phase 1b randomised, placebo controlled clinical trial was designed to evaluate the blood plasma levels of SMT C1100 in paediatric patients with DMD. Patients and their caregivers were provided with specific dietary guidance on recommended balanced proportions of fats, proteins and carbohydrates. The trial enrolled a total of 12 patients aged between 5 and 13 years, divided equally into three dose cohorts, at trial sites in the UK. Patients were randomised to three groups over 14-day treatment periods during which each patient received two different doses of SMT C1100 and a placebo control. There was a washout period of at least 14 days in between each of the treatment periods.

About Utrophin Modulation in DMD
DMD is a progressive muscle wasting disease that affects around 50,000 boys in the developed world. The disease is caused by different genetic faults in the gene that encodes dystrophin, a protein that is essential for the healthy function of all muscles. There is currently no cure for DMD and life expectancy is into the late twenties. Utrophin protein is functionally and structurally similar to dystrophin. In preclinical studies, the continued expression of utrophin has a meaningful, positive effect on muscle performance. Utrophin modulation has the potential to slow down or even stop the progression of DMD, regardless of the underlying dystrophin mutation. It is also expected that utrophin modulation could potentially be complementary to other therapeutic approaches for DMD.

About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:

**Summit**
Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 255 4455

**Cairn Financial Advisers LLP**
(Nominated Adviser)
Liam Murray / Tony Rawlinson Tel: +44 (0)20 77148 7900

**N+1 Singer**
(Broker)
Aubrey Powell / Jen Boorer Tel: +44 (0)20 7496 3000

**Peckwater PR**
(Financial public relations, UK)
Tarquin Edwards Tel: +44 (0)7879 458 364
tarquin.edwards@peckwaterpr.co.uk

**MacDougall Biomedical Communications**
(US media contact)
Chris Erdman Tel: +1 781 235 3060
cerdman@macbiocom.com

-END-